A retrospective study from Japan27 confirmed interferon beta and temozolomide for patients with newly diagnosed primary GBM achieved a greater OS of 19.9 months when compared with 12.7 months for standard temozolomide treatment, particularly in patients with unmethylated MGMT promoter with prolonged OS of 17.2 months, which supported our study findings. Here, IFNB1 is linked to glioblastoma.